CUPERTINO, Calif., April 25,
2023 /PRNewswire/ -- DURECT Corporation (Nasdaq:
DRRX) today announced that Dr. James
Brown, President and CEO, will participate in a fireside
chat hosted by Ed Arce, Managing
Director, Senior Biotechnology Research Analyst, H.C Wainwright & Co., LLC at the H.C.
Wainwright BioConnect Investor Conference on May 2, 2023.
Details are as follows:
H.C. Wainwright BioConnect Investor Conference
Date:
|
May 2, 2023
|
Time:
|
10:00 AM Eastern
Time
|
Format:
|
Fireside Chat hosted by
Ed Arce
|
Webcast:
|
https://journey.ct.events/view/69fb9cb7-377f-4a5d-b65b-15dd26f05f7c
|
The webcast link will also be available by accessing DURECT's
homepage at www.durect.com and clicking on "Events" under the
"Investors" section. A replay will be available for 90 days.
About DURECT Corporation
DURECT is a biopharmaceutical
company committed to transforming the treatment of acute organ
injury and chronic liver diseases by advancing novel and
potentially lifesaving therapies based on its endogenous epigenetic
regulator program. Larsucosterol (also known as DUR-928), DURECT's
lead drug candidate, binds to and inhibits the activity of DNA
methyltransferases (DNMTs), DNA-modifying enzymes that are elevated
and associated with the hypermethylation found in patients with
severe alcohol-associated hepatitis (SAH). Larsucosterol is in
clinical development for the potential treatment of SAH, for which
FDA has granted a Fast Track Designation. Non-alcoholic
steatohepatitis (NASH) is also being explored. In addition,
POSIMIR® (bupivacaine solution) for infiltration use, a
non-opioid analgesic utilizing the innovative SABER®
platform technology, is FDA-approved and has been exclusively
licensed to Innocoll Pharmaceuticals for commercialization in
the United States. For more
information about DURECT, please visit www.durect.com and follow us
on Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statements
This press release contains forward-looking statements, including
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, relating to: our
plans to complete enrollment of the AHFIRM trial in the second
quarter of 2023 and report topline data in the second half of 2023,
the potential FDA approval of larsucosterol for the treatment of
AH, the ability of a positive outcome in the AHFIRM trial to
support a New Drug Application filing, the commercialization of
POSIMIR by Innocoll, the potential to develop larsucosterol for AH,
NASH or other indications, and the potential benefits, if any, of
our product candidates. Actual results may differ materially from
those contained in the forward-looking statements contained in this
press release, and reported results should not be considered as an
indication of future performance. The potential risks and
uncertainties that could cause actual results to differ from those
projected include, among other things, the risks that the AHFIRM
trial takes longer to conduct than anticipated due to COVID-19 or
other factors, the risk that ongoing and future clinical trials of
larsucosterol do not confirm the results from earlier clinical
or pre-clinical trials, or do not demonstrate the safety or
efficacy of larsucosterol in a statistically significant
manner, the risk that the FDA or other government agencies may
require additional clinical trials for larsucosterol before
approving it for the treatment of AH even if the results of the
AHFIRM trial are successful, risks that Innocoll may not
commercialize POSIMIR successfully, and risks related to the
sufficiency of our cash resources, our anticipated capital
requirements, our need or desire for additional financing, our
ability to obtain capital to fund our operations and expenses and
our ability to continue to operate as a going concern. Further
information regarding these and other risks is included in DURECT's
most recent Securities and Exchange Commission (SEC) filings,
including its annual report on Form 10-K for the year ended
December 31, 2022 under the heading
"Risk Factors." These reports are available on our
website www.durect.com under the "Investors" tab and on
the SEC's website at www.sec.gov. All information provided in
this press release is based on information available to DURECT as
of the date hereof, and DURECT assumes no obligation to update this
information as a result of future events or developments, except as
required by law.
NOTE: POSIMIR® is a trademark of Innocoll
Pharmaceuticals, Ltd. in the U.S. and a trademark of DURECT
Corporation outside of the U.S. SABER® is a trademark
of DURECT Corporation. Other referenced trademarks belong
to their respective owners. Larsucosterol (DUR-928) is an
investigational drug candidate under development and has not been
approved for commercialization by the U.S. Food and Drug
Administration or other health authorities for any
indication.
View original
content:https://www.prnewswire.com/news-releases/durect-corporation-to-participate-in-fireside-chat-at-the-hc-wainwright-bioconnect-investor-conference-301807559.html
SOURCE DURECT Corporation